| 43.96 0.11 (0.25%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.25 | 1-year : | 61.03 |
| Resists | First : | 44.74 | Second : | 52.25 |
| Pivot price | 41.99  |
|||
| Supports | First : | 39.04 | Second : | 35.52 |
| MAs | MA(5) : | 43.68 |
MA(20) : | 40.8 |
| MA(100) : | 40.9  |
MA(250) : | 39.84 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 89.5 |
D(3) : | 88.5 |
| RSI | RSI(14): 67.4 |
|||
| 52-week | High : | 50.99 | Low : | 27.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XENE ] has closed below upper band by 24.2%. Bollinger Bands are 61.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.49 - 44.66 | 44.66 - 44.79 |
| Low: | 43.05 - 43.26 | 43.26 - 43.42 |
| Close: | 43.65 - 43.97 | 43.97 - 44.23 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Thu, 25 Jul 2024
Stock Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
Thu, 25 Jul 2024
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Thu, 25 Jul 2024
Stock Traders Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - Defense World
Wed, 24 Jul 2024
BNP Paribas Financial Markets Acquires 3,931 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Sun, 21 Jul 2024
Westfield Capital Management Co. LP Buys 109,856 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Thu, 27 Jun 2024
Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 75 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 100.3 (%) |
| Shares Short | 3,050 (K) |
| Shares Short P.Month | 2,990 (K) |
| EPS | -2.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.76 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.1 % |
| Return on Equity (ttm) | -24 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -154 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -16.17 |
| PEG Ratio | -1.7 |
| Price to Book value | 3.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|